Skip to content

Burden of Hepatitis D Virus (HDV) Infection in Italy

Burden of Hepatitis D Virus (HDV) Infection in Italy: a Prospective/Observational Multicenter Study to Define Demographic, Clinical and Virological Features

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05723068
Acronym
HDV Describe
Enrollment
515
Registered
2023-02-10
Start date
2022-08-24
Completion date
2024-12-31
Last updated
2025-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis D

Brief summary

The circulation of the Hepatitis D Virus (HDV) has considerably diminished in Italy, secondary to the control of the Hepatitis B Virus (HBV) with vaccination; this has led to the perception that HDV is vanishing and has reduced attention to the diagnosis of Hepatitis D. However, migratory fluxes from HDV endemic areas, fostered by labour-forces globalization, are increasingly reconstituting the reservoir of HDV in the country and hepatitis D has not yet vanished in native Italians but will remain an important medical issue for several years to come. As the epidemiologic and clinical features of HDV infection in migrant communities are largely unknown and the features of native Italians with long standing HDV infections have not been updated, this project intends to establish the contemporary epidemiological and medical context of HDV in immigrants in Italy and to determine the clinical characteristics and needs of the residual cohort of native HDV Italians, through the analysis of all HDV cases recruited in 12 months in a coordinated network of 35 Italian medical centers. The data will provide an appraisal of the burden of hepatitis D in the country and of its impact on the National Health System. They will present the paradigm of the current trend of HDV infection in high-income countries in the world.

Interventions

None listed

Sponsors

Gilead Sciences
CollaboratorINDUSTRY
University of Turin, Italy
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HBsAg-positive subjects * 18 years or older * anti-HD-positive

Design outcomes

Primary

MeasureTime frameDescription
HBsAg concentration levels in HDV-infected patients1 yearHBsAg means hepatitis B surface antigen. HDV means hepatitis D virus
Demographic characteristics of HDV-infected patients1 yearDemographic characteristics: age, sex, height, weight, nationality. HDV means hepatitis D virus
Epidemiologic characteristics of HDV-infected patients1 yearRisk factors for infection. HDV means hepatitis D virus
Serum alanine aminotransferase concentration values in HDV-infected patients1 yearHDV means hepatitis D virus
Blood platelet count in HDV-infected patients1 yearHDV means hepatitis D virus
Serum albumin concentration values in HDV-infected patients1 yearHDV means hepatitis D virus
Serum total bilirubin concentration values in HDV-infected patients1 yearHDV means hepatitis D virus
Serum anti-liver-kidney microsomal antibodies titer in HDV-infected patients1 yearHDV means hepatitis D virus
Proportion of patients with detectable HDV RNA among seropositive anti-HDV patients1 yearHDV means hepatitis D virus
Serum HDV RNA levels in HDV-infected patients1 yearHDV means hepatitis D virus
Proportion of HDV genotypes among patients with detectable HDV RNA1 yearHDV means hepatitis D virus
Proportion of patients with detectable HBV DNA among seropositive anti-HDV1 yearHBV means hepatitis B virus. HDV means hepatitis D virus
Serum HBV DNA levels in HDV-infected patients1 yearHBV means hepatitis B virus. HDV means hepatitis D virus
Proportion of HBV genotypes among patients with detectable HBV DNA1 yearHBV means hepatitis B virus
HBcrAg concentration levels in HDV-infected patients1 yearHBcrAg means hepatitis B core-related antigen. HDV means hepatitis D virus
Proportion of patients with liver cirrhosis among seropositive anti-HDV1 yearHDV means hepatitis D virus
Liver stiffness values in HDV-infected patients1 yearHDV means hepatitis D virus
Proportion of patients with hepatocellular carcinoma among seropositive anti-HDV1 yearHDV means hepatitis D virus
Proportion of patients treated with antiviral therapy among seropositive anti-HDV1 yearHDV means hepatitis D virus

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026